Overview

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
0
Participant gender:
All
Summary
The study will compare the effectiveness of antipsychotic medications for patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular disease.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Institute of Mental Health (NIMH)
Treatments:
Antipsychotic Agents
Aripiprazole
Olanzapine
Quetiapine Fumarate
Risperidone
Criteria
Inclusion Criteria:

- Diagnosed with schizophrenia or schizoaffective disorder

- Currently treated with olanzapine, quetiapine or risperidone

- BMI greater than or equal to 27

- Non-HDL cholesterol greater than or equal to 130 mg/dL (if non-HDL cholesterol is
between 130 - 139 mg/dL, then LDL cholesterol must be greater than 100 mg/dL).

Exclusion Criteria:

- Diabetes (FBS greater than or equal to 126) or treatment with oral hypoglycemic drug
or insulin

- Non-HDL cholesterol greater than 300 mg/dL

- Serum triglycerides greater than 500 mg/dL

- Patients in the first episode of schizophrenia or schizoaffective disorder

- Known hypersensitivity to aripiprazole

- On weight loss medications